An NCI-designated Comprehensive Cancer Center

Tanya Siddiqi, M.D.

Hematologist - Oncologist
Clinical Expertise
Director, Chronic Lymphocytic Leukemia Program, Toni Stephenson Lymphoma Center; Associate Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation

Clinical Teams

Tanya Siddiqi, M.D., is an accomplished hematologist-oncologist who specializes in diagnosing and treating blood cancers, particularly leukemia and lymphoma. She is also a supervising physician at City of Hope's anti-coagulation clinic, which treats patient with blood clotting disorders due to their diseases or treatments.

In addition to her clinical practice, Dr. Siddiqi is also principal investigator on a number of clinical trials evaluating the role of targeted therapies, including gene therapy (CAR T cell therapy), and other novel agents primarily in diseases like chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

Dr. Siddiqi earned her medical degree at Aga Khan University Medical College in Karachi, Pakistan. Afterward, she completed an internal medicine residency at University of Connecticut Health Center, followed by two fellowships: hematology/oncology at Beth Israel Deaconess Medical Center (Harvard Medical School, Boston) and hematopoietic stem cell transplantation at City of Hope.

Dr. Siddiqi is a member of the Toni Stephenson Lymphoma Center and the Gehr Family Center for Leukemia Research.


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

  • Siddiqi T, Frankel P, Ruel C, Beumer JH, Song JY, Scuto A, Chen R, Kelly KR, Tuscano J, Popplewell L, Puverel S, Thomas S, Forman SJ, Piekarz R, Newman E. Phase 1 study of Aurora kinase A inhibitor alisertib (MLN8237) and histone deacetylase inhibitor vorinostat in lymphoid malignancies. Manuscript in preparation.
  • Khan M, Siddiqi R, Siddiqi T. The role of prognostic markers in the era of targeted therapy for chronic lymphocytic leukemia. Editorial submitted.
  • Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Cin PD, Pak C, Alyea EP, Budde E, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P. “Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma”. Biol Blood Marrow Transplant. 2017 Nov 28. pii: S1083-8791(17)30870-4. DOI: 10.1016/j.bbmt.2017.11.023. [Epub ahead of print] PMID: 29196080
  • Mei MG, Cao TM, Chen L, Song J, Siddiqi T, Cai JL, Farol LT, Al Malki MM, Salhotra A, Aldoss I, Palmer J, Herrera AF, Zain J, Popplewell LL, Chen RW, Rosen ST, Forman SJ, Kwak L, Nademanee AP, Budde LE. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Biol Blood Marrow Transplant. 2017 Jul 18. pii: S1083-8791(17)30575-X. DOI: 10.1016/j.bbmt.2017.07.006. [Epub ahead of print]
  • Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiyang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go W. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy 2017 Jan; 25(1):285-295
  • Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen ED. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leuk Lymphoma. 2017 Jul;58(7):1607-1616. doi: 10.1080/10428194.2016.1256481. Epub 2016 Nov 20.
  • Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohail AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol 2017 Jan; 35: 24-31. Epub 2016 Oct 24. PMID: 28034071
  • O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct;17(10):1409-1418. DOI: 10.1016/S1470-2045(16)30212-1. Epub 2016 Sep 13. PMID: 27637985
  • Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, Norris AP, Wong CW, Urak RZ, Chang WC, Khaled SK, Siddiqi T, Budde LE, Xu J, Chang B, Gidwaney N, Thomas SH, Cooper LJ, Riddell SR, Brown CE, Jensen MC, Forman SJ. “Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.” Blood. 2016 Jun 16;127(24):2980-90. DOI: 10.1182/blood-2015-12-686725. Epub 2016 Apr 26. PMID: 27118452
  • Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. “Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.” N Engl J Med. 2015 Dec 17;373(25):2425-37. DOI: 10.1056/NEJMoa1509388. Epub 2015 Dec 6. PMID: 26639149
  • Song JY, Venkatarama G, Fedoriw Y, Herrera AF, Siddiqi T, Alikhan MB, Kim YS, Murata-Collins J, Weisenburger DD, Liu X, Duffield AS. “Burkitt leukemia limited to the bone marrow has a better prognosis than Burkitt lymphoma with bone marrow involvement in adults.” Leuk Lymphoma 2015; 1-6 [epub ahead of print]. PMID: 26450341
  • Streiff MB, Holmstrom B, Ashrani A, Bockenstedt PL, Chesney C, Eby C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Hendrie P, Kuderer N, Lee JT, Lovrincevic M, Millenson MM, Neff AT, Ortel TL, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang TF, Yee GC, Zakarija A, McMillian N, Engh AM. “Cancer-associated Venous thromboembolic disease, version 1.2015.” J Natl Compr Canc Netw 2015; 13 (9): 1079-95. PMID: 26358792
  • Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, Popplewell L, Siddiqi T, Thomas SH, Mott M, Sahebi F, Armenian S, Leonard J, Nademanee A, Forman SJ. “Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.” Biol Blood Marrow Transplant. 2015 Dec;21(12):2136-40. DOI: 10.1016/j.bbmt.2015.07.018. Epub 2015 Jul 26. PMID: 26211987
  • Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cahsen AF, Cohen JB, D’Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B, Maloney DG, Smith SM, Sureda AM, Carreras J, Hamdani M; Center for International Blood and Marrow Transplant Research Lymphoma Working Committee. “Impact of pretransplantation (18)F-fluorodeoxy glucose-positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.” Biol Blood Marrow Transplant 2015; 21: 1605-11. DOI: 10.1016/j.bbmt.2015.05.007. Epub 2015 May 14. PMID: 25983043
  • Siddiqi T, Rosen ST. “Novel Biologic Agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia – Part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.” Oncology (Williston Park) 2015; 29: 299-308. Review. PMID: 25920929
  • Siddiqi T, Rosen ST. “Novel Biologic Agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia – Part 1.” Oncology (Williston Park) 2015; 29: 198-203. Review. PMID: 25772456
  • Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A, Thomas SH, Mott M, Nathwani N, Htut M, Nademanee A, Forman SJ, Kirschbaum M. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica. 2015 Mar;100(3):357-62. DOI: 10.3324/haematol.2014.117473. PMID: 25596263
  • Chen R, Palmer JM, Tsai NC, Thomas SH, Siddiqi T, Popplewell L, Farol L, Nademanee A, Forman SJ. “Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.” Biol Blood Marrow Transplant 2014; 20: 1864-8. PMID: 25008328
  • Siddiqi T, Thomas SH, Chen R. “Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.” Pharmacogenomics Pers Med 2014 Feb 20; 7: 79-85. PMID: 24672256
  • Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA, Siddiqi T, Kennedy DA, Oki Y. “Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.” Blood 2014 May 15; 123 (20): 3095-100. PMID: 24652992
  • Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, Fogerty AE, Gao S, Goldhaber SZ, Hassoun H, Hendrie P, Holmstrom B, Kuderer N, Lee JT, Millenson MM, Neff AT, Ortel TL, Siddiqi T, Smith JL, Yee GC, Zakarija A, McMillian N, Naganuma M. “Venous thromboembolic disease.” J Natl Compr Canc Netw 2013 Nov; 11 (11): 1402-29. PMID: 24225973
  • Siddiqi T, Blaise D. “Does antithymocyte globulin have a place in reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation?” Hematology Am Soc Hematol Educ Program 2012: 246-50. PMID: 23233588
  • Will B, Siddiqi T (co-1st author), Jorda MA, Shimamura T, Luptakova K, Staber PB, Costa DB, Steidl U, Tenen DG, Kobyashi S. “Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.” Blood 2010 Apr 8; 115 (14): 2901-9. PMID: 20160166
  • Melicoff E, Sansores-Garcia L, Gomez A, Moreira DC, Datta P, Thakur P, Siddiqi T, Murthy J, Dickey BF, Heidelberger R, Adachi R. “Synaptotagmin-2 controls regulated exocytosis but not other secretory responses of mast cells.” J Biol Chem 2009 Jul 17; 284 (29): 19445-51. PMID: 19473977
  • Siddiqi T, Joyce RM. A case of HIV negative primary effusion lymphoma treated with bortezomib, liposomal doxorubicin and rituximab. Clin Lymphoma Myeloma 2008 Oct; 8 (5): 300-4. PMID: 18854285
  • Siddiqi T, Bauer KA, Barbieri RL. Contraception for women with inherited thrombophilias. Up To Date online, 2008 Oct.; updated each year.
  • Abbas F, Memon  A, Siddiqui T, Kayani N, Ahmad  NA. “Granular cell tumors of the urinary bladder.” World J Surg Oncol, 2007 Mar 13; 5:33. PMID: 17355632
  • Ikram M, Khan MA, Ahmed M, Siddiqui T, Mian MY. “The histopathology of routine tonsillectomy specimens: results of a study and review of literature.” Ear Nose Throat J. 2000 Nov; 79 (11): 880-2. PMID: 11107690
  • Ahmed M, Khan AA, Siddiqi T, Ikram M, Mian MY. “A Comparison of Dissection-method and Diathermy Tonsillectomies.” J Pak Med Assoc. 2000 Jul; 50 (7): 215-6. PMID: 10992695
  • Siddiqui T, Pervez S. “Spectrum of Hodgkin’s disease in children and adults: impact of combined morphologic and phenotypic approach for exclusion of ‘look-alikes’.” J Pak Med Assoc. 1999 Sep; 49 (9): 211-4. PMID: 10646321


  • Afkhami M, Siddiqi T, Rosen S. “Case study section: Lymphoplasmacytic lymphoma in the era of next generation sequencing.” Lymphoma handbook 2017: A case-based approach. Editors: Zain J, Kwak L. Publisher: Springer
  • Siddiqi T, Rosen ST. “B-SLL and CLL.” Lymphoma handbook 2017: A case-based approach. Editors: Zain J, Kwak L. Publisher: Springer
In The News
An Expert's Voice
Chuck Fata was involved in a CAR T cell trial at City of Hope.

Making a Comeback


City of Hope Physicians Announce New CAR T Breakthroughs at Annual ASH Meeting

City of Hope News

City of Hope physicians report on new CAR T cell therapy for acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm at American Society of Hematology annual meeting